Phathom Pharmaceuticals Inc
PHAT
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.01B
Close$
$-4.09
137.1% downside
Current Fair Value
137.1% downsideOvervalued by 137.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.01 Billion |
|---|---|
| Enterprise Value | $827.45 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.03 |
| Beta | 0.49 |
| Outstanding Shares | 82,050,618 |
Return
| Return on Equity | -36.89% |
|---|---|
| Return on Assets | 40.73% |
| Return on Invested Capital | 128.21% |
Valuation & Multiples
| P/E Ratio | -5.95 |
|---|---|
| PEG | - |
| Price to Sales | 5.52 |
| Price to Book Ratio | -2.21 |
| Enterprise Value to Revenue | 4.04 |
| Enterprise Value to EBIT | 3.58 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$58.84 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$73.98 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 5.77% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.02%▼ 92.46% |
|---|---|
| Total Invested | $17.95M▼ 97.65% |
| Investors Holding | 6▼ 173.00% |
ESG Score
No data
About Phathom Pharmaceuticals Inc
55 employeesPhathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, E...